If I'm reading that first graph correctly, which is for the whole tested population, the averaged pain reduction for iPPS is only at best about 6% less than the placebo. So what I'm interpreting is that for some severe pain sufferers a more substantial reduction is found ( previous announcement) , but averaged out over the whole population tested it does not look to be too impressive. Or am I dead wrong?
Ann: Paradigms Supplementary Phase 2B Data, page-4
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
-0.005(2.04%) |
Mkt cap ! $83.98M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.5¢ | 24.0¢ | $202.2K | 814.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 181098 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 118621 | 5 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |